Development and Assessment of Novel Therapeutic Formulation for the Lipoma Treatment

Lipomas are slow-growing, mostly usually benign fatty tumors. The subcutaneous tissues are where they are most commonly found. Most lipomas are clinically identifiable, asymptomatic, and incurable. These tumors may also be found in deeper tissues such as the thorax, the internal auditory canal, the oral cavity, the abdominal organs, the intermuscular septa, and the cerebellopontine angle. While 2-4 lipomas can occur in people of any age, they usually initially appear in those between the ages of 40 and 60. Congenital lipomas have been described in children. Some lipomas are believed to have developed as a result of severe trauma. Women are more likely to have a single lipoma, while men are more likely to have many tumors, or lipomatosis. Multiple lipomatosis with autosomal dominance Gardner's syndrome, an autosomal dominant illness characterized by intestinal polyposis, cysts, and osteomas, may also be associated with lipomatosis. This disorder is characterized by widespread symmetric lipomas that usually appear over the trunk and limbs and are most common in men. Benign symmetric lipomatosis, also known as Madelung's disease, is the term used to describe lipomatosis of the head, neck, shoulders, and proximal upper extremities. The characteristic "horse collar" cervix can be seen in people with Madelung's illness, who are usually men who drink. Lipomas usually appear as round, moveable masses with a characteristic soft, doughy texture that are painless. The skin on top appears to be normal. On the basis of their clinical appearance alone, lipomas are usually appropriately diagnosed. Under a microscope, lipomas are composed of mature adipocytes arranged in lobules, many of which are covered in a fibrous capsule. When a nonencapsulated lipoma occasionally penetrates muscle,it is referred to as an infiltrating lipoma.^[1]

Fig no. 01

A biopsy specimen may reveal four additional lipoma kinds.

1. Angioliopoma: Include several small blood arteries as well as mature fat cells. often more excruciating than typical lipomas.

2. Lipoma spindle cell: Include spindle-shaped cells and mature fat. usually observed on the back, neck, or shoulders of older men.

3. Lipoma Myxoid: Has a gelatinous, myxoid stroma around its fat cells. Under a microscope, it appears more mucous and softer.

4. Lipoma pleomorphic: involves unusual, multinucleated enormous cells in addition to fat and spindle cells. mostly affects the neck and back.^[2]

Lipomas can occasionally, albeit infrequently, be associated with illnesses such as multiple hereditary lipomatosis, Gardner syndrome, adiposis dolorosa, and Madelung disease. ^[3][4] Angiolipoma, chondroid lipoma, lipoblastoma, myolipoma, pleomorphic lipoma/spindle cell lipoma, intramuscular and intermuscular lipoma, nerve lipomatosis, tendon sheath and joint lipoma, lipoma arborescens, multiple symmetric lipomatosis, diffuse lipomatosis, adiposis dolorosa, and hibernoma are some of the uncommon types of lipomas.

1.1 Lipoma can also be:

Deep-seated, happening within muscles or organs such as the liver and kidney. Multiple, particularly in heritable disorders such as familial multiple lipomatosis. Although encapsulated, it can occasionally infiltrate adjacent tissues, complicating removal.

1.1.1 Mechanism of action of lipoma

A lipoma forms when adipocytes, or fat cells, in a specific area of the body begin to proliferate and grow at an abnormally high rate. This produces a non-cancerous soft lump beneath the skin. Although the actual cause is not always evident, the following important elements may contribute to this:

Genetic Alterations: Mutations in the HMGA2 gene, for example, can cause excessive fat cell development.

Stem Cell Imbalance: Mesenchymal stem cells, the body's repair cells, can mistakenly differentiate into fat cells and create a mass.

Trauma or Minor Injury: In some situations, trauma can cause fat tissue to expand in an abnormal manner. Family History: A predisposition to develop numerous lipomas is inherited by some indi viduals. ^[5]

Fig no.02

1.2 Causes of Lipoma

1. Genetic factors

• most common cause, especially in case of multiple lipomas.
• Condition like familial multiple lipomas are inheridated.
• Gene mutation.

2. Metabolic Disorders:

Certain metabolic conditions may increase the risk:

• Madelang’s disease (multiple symmetrical lipomatosis)
• Diabetes
• Dyslipidemia (abnormal fat levels in blood)

3. Age:

• Lipomas are most common in people aged 40to 60
• Rare in children and young adults

4. Family History

• A strong genetic predisposition exist in many cases.
• People with a family history of lipoma are more likely to develop them.

1.3 Common early warning signs can include:

Soft, painless lump: A soft, rubbery lump beneath the skin is usually the first noticeable symptom.

Slow growth: The lump typically increases slowly over a few weeks or months. The bulge is often moveable with light pressure beneath the skin.

Size: Usually little (less than 5 cm), but occasionally bigger.

No skin changes: In general, the skin around the mass is not red, heated, or infected.

Usually painless: Lipomas are typically asymptomatic, but if they press against muscles or nerves, they may occasionally cause pain. ^[6]

Anatomical Pathology

Mesenchymal tumors, usually located subcutaneously, are referred to as lipomas.[7] They can also be found on internal organs including the colon and stomach; however this is less common. Usually, these masses are not connected to the muscular tissue beneath them. Lobulated, mature, slow-growing adipose tissue with little connective tissue stroma makes up lipomas. Usually, a thin, fibrous capsule encloses them.

Variants of lipoma defined by location include:

• Intermuscular lipoma
• Intramuscular lipoma
• Parosteal/ periosteal lipoma
• Lipoma arborescens (synovial lipomatosis)
• Intracranial lipoma

CLINICAL PATHOLOGY

Patients frequently report feeling a mobile, squishy mass of tissue beneath their skin. Unless they invade blood vessels, joints, or nerves, these are usually harmless. These are frequently observed by patients in the upper body. These lipomas might infrequently develop in organs or muscles. Most lipomas are benign, and they are only removed or treated if their position causes pain or if they interfere with an organ's ability to function. However, because these tumors are often visible through the skin due to their subcutaneous location, some patients decide to have them removed for aesthetic purposes. Small incisions can be used to remove lipomas smaller than 4 cm, and scarring is typically not a major concern. According to research, open surgery is still a better option than suction-assisted lipectomy through small incisions for the removal of giant lipomas (greater than 10 cm) because it allows for better judgment, prevents recurrences, and avoids damage to the surrounding tissues. ^[8]

Treatment and Management

Unless they create discomfort, cosmetic issues, or functional issues, most lipomas don't need to be treated.

5. Surgical Excision

The most popular course of treatment is surgical removal. To stop recurrence, the tumor and its capsule are removed.

5. Liposuction

In some cases, liposuction may be used to remove fatty tissue through a small incision.^[9]

5. Steroid Injections

Lipomas may not be totally eradicated by steroid injections, but they can be made smaller.

5. Emerging Treatments:

Researchers are exploring non-surgical treatments including:

Injectable fat-dissolving agents

Targeted drug delivery systems

Hydrogel-based localized therapy

These approaches aim to reduce tumor size with minimal invasive procedures.^[10]

Clinical Significance

While lipomas can appear at any age, they usually do so in people between the ages of 40 and 60, and there is no evidence of gender bias. Other age groups are more likely to experience certain forms of lipomas. For instance, lipoblastomas and diffuse lipomatosis are frequently observed in children beyond the age of three, while hibernomas typically manifest clinically at the age of thirty. Five percent of patients have more than one lipoma.

According to reports, 1% of people have lipomas, and their incidence—which may be underreported—is 2.1 per 1000 people year.

A positive diagnosis of a lipoma typically involves the following: 

• Physical exam performed by a medical doctor
• An ultrasound of the mass should reveal that the lipoma or adipose mass is deeper than the surrounding fatty tissue and that it has different characteristics from the adipose tissue that is healthy or normal.
• A biopsy (and subsequent examination of a tissue sample) is not performed routinely in standard practice because the diagnosis is typically made clinically, and it may be difficult to identify lipomas from healthy adipose tissue histologically.

Surveillance

If lipomas are not painful and harmless, there is no need for removal. 

Treatment

These methods include liposuction of the tumor, surgical excision, intralesional steroids mixed with isoproterenol (a beta-2 adrenergic agonist), and intralesional transcutaneous sodium deoxycholate (related or not to phosphatidylcholine) injections. The latter is probably the best way to stop them from happening again, but for the best course of action and to lower the chance of recurrence, the encapsulation must also be removed.[11] In order to minimize the possibility of lipomas encroaching on joints, nerves, and blood arteries, which would make the excision more challenging and invasive, it is best to remove lipomas when they are still small rather than after they have grown larger.

Prognosis

Benign lipomas have an excellent prognosis. There is no chance that these benign entities may develop into malignant ones.[12] These tumors frequently do not recur after being removed, mostly for cosmetic purposes. To avoid this, however, the fibrous capsule encircling the lipoma must be completely removed.

Classification

World Health Organization (WHO) classification system classified lipomatous tumors into the following sub types^[13]

• Lipoma
• Lipomatosis
• Lipomatosis of nerve
• Lipoblastoma/ lipoblastomatosis
• Angiolipoma
• Myolipoma of soft tissue
• Chondroid lipoma
• Spindle-cell lipoma/pleomorphic lipoma
• Hibernoma.

Table no 1.1: Marketed products used to treat lipoma

Brand Name	Ingredients	Image
Bakson’s Lipoma Aid Drops	Calcarea Fluorica, Baryta Carbonica, Thuja occidentalis
Kybella	Deoxycholic acid (ATX-101)
Ayurvedic Lipoma Capsules	Triphala, Guggul, Turmeric, Haritaki, Bibhitaki
Trilone Injection	Triamcinolone acetonide

Mechanism of Action of Active Ingredients

Green tea:

Biologically active polyphenols called catechins, especially Epigallocatechin gallate, are found in green tea extract and are crucial for lipid metabolism. Green tea catechins increase lipolysis in the context of catecholamine stimulation by norepinephrine, according to in vitro research utilizing differentiated adipocyte cell lines such 3T3-L1. Treatment with catechin causes adipocytes to produce more glycerol and free fatty acids, which suggests that stored triglycerides are being broken down more effectively. Important lipolytic enzymes including hormone-sensitive lipase are activated and phosphorylated during this process. Furthermore, the first phase of triglyceride hydrolysis is catalyzed by Adipose Triglyceride Lipase, whose mRNA and protein expression levels are increased by catechins. Additionally, green tea catechins block Catechol-O-methyltransferase, which prolongs norepinephrine's effect and increases lipolysis. Green tea extract stimulates overall fat metabolism, enhances fatty acid mobilization, and encourages triglyceride breakdown through several processes. ^[14]

Quercetin:

Quercetin has a number of biological effects that could help treat lipomas. By suppressing adipogenic transcription factors including PPAR-γ and C/EBPα, which are necessary for the transformation of pre-adipocytes into mature adipocytes, it prevents adipogenesis. Quercetin inhibits the production of new fat cells in lipomatous tissue by blocking several processes. Furthermore, quercetin increases the breakdown of stored triglycerides into free fatty acids and glycerol via activating AMP-activated protein kinase (AMPK). Its potent antioxidant properties aid in reducing oxidative stress and neutralizing reactive oxygen species, both of which may be factors in aberrant adipose tissue growth. Additionally, by blocking inflammatory mediators including TNF-α and NF-κB signaling pathways in adipose tissue, quercetin demonstrates strong anti-inflammatory effects. Additionally, it alters the enzymes involved in lipid metabolism, enhancing the metabolic equilibrium of fat cells. When taken as a whole, these strategies may limit the growth of lipomas, lessen the accumulation of lipids, and eventually diminish the size of lipomas while lowering the risk of recurrence. ⁽¹⁵⁾

Boswellia serrata:

Boswellic acids, particularly AKBA (Acetyl-11-keto-β-boswellic acid), are active chemicals found in Boswellia serrata resin that have therapeutic and anti-inflammatory actions via a variety of metabolic routes.

1. Inhibition of 5-Lipoxygenase (5-LOX)

• The enzyme 5-lipoxygenase is specifically inhibited by boswellic acids.
• 5-LOX transforms arachidonic acid into leukotrienes (LTB4, LTC4, and LTD4).
• Leukotrienes are potent mediators of edema, bronchoconstriction, and inflammation.
• Boswellia inhibits this enzyme, which lowers leukotriene production and thus inflammation in illnesses such as arthritis, asthma, and inflammatory bowel disease.

2. Reduction of Leukocyte Elastase

• Boswellic acids inhibit human leukocyte elastase (HLE).
• HLE damages connective tissue during chronic inflammation.
• Inhibition prevents tissue destruction and cartilage degradation, which is beneficial in  osteoarthritis and rheumatoid arthritis.

3. Inhibition of Pro-Inflammatory Cytokines

Boswellia suppresses the release of inflammatory mediators such as:

• TNF-α (Tumor Necrosis Factor-alpha)
• IL-1β
• IL-6

This occurs by blocking activation of the transcription factor NF?κB, which regulates many inflammatory genes.

4. Inhibition of Matrix Metalloproteinases (MMPs)

• Boswellic acids inhibit MMP-3 and MMP-9, enzymes responsible for cartilage breakdown.
• This contributes to chondroprotective activity in joint diseases

5. Inhibition of Complement System

• Boswellia suppresses activation of the classical complement pathway, reducing immune-mediated inflammation.

6. Antioxidant Activity

• Boswellia compounds scavenge reactive oxygen species (ROS) and reduce oxidative stress at inflamed sites.

7. Anti-Proliferative and Anti-Tumor Effects

AKBA:

• Induces apoptosis in cancer cells
• Inhibits topoisomerase I and II
• Blocks angiogenesis (VEGF signaling)

This contributes to its studied role in cancers and brain tumors.

8. Effects on Immune Modulation

• Modulates T-cell and B-cell activity
• Reduces excessive immune response while maintaining normal immunity.^[16]

List of materials

Table no.1.2: List of materials

List of Equipment, Instrument, Glassware

Table no.1.3: List of Equipment, Instrument, Glassware

PLANT PROFILE

GREEN TEA:

Table No. 1.4 Profile of Green Tea

Fig no. 03 : structure of Green tea

Fig no.04 : Green tea

Lipolytic Agent

Catechins and caffeine, two of green tea's active ingredients, work together to encourage the breakdown and use of stored fat.

The primary catechin in green tea, epigallocatechin gallate (EGCG), has the ability to block the enzyme catechol-O-methyltransferase (COMT).

Norepinephrine, a hormone that burns fat, is broken down by this enzyme. EGCG stimulates and prolongs the function of norepinephrine, which tells fat cells to break down stored fat, via blocking COMT.

Increases norepinephrine: The enzyme that breaks down the hormone norepinephrine can inhibited by green tea catechins, particularly EGCG. Norepinephrine levels rise as a result, which encourages lipolysis.

BOWELLIA SERRATA:

Table No. 1.5 Profile of Boswellia Serrata

Figno.05  Strucutre of Boswellia Serrata

Fig no.06 Boswellia Serrata

Anti-inflammatory properties

Inhibits pro-inflammatory enzymes: Boswellia serrata's boswellic acids, especially 3-O-acetyl-11-keto β beta ????-boswellic acid (AKBBA), are strong inhibitors of 5-lipoxygenase (5-LOX).

Lowers inflammatory mediators: Boswellia serrata lowers the synthesis of leukotriene and other pro-inflammatory molecules that cause inflammation by blocking 5-LOX.

Suppresses inflammatory mediators: It can lower the expression of adhesion molecules and suppress other inflammatory markers and enzymes, including cyclooxygenases (COX) and nitric oxide (NO)

QUERCETIN:

Table no.1.6: Profile of quercetin

Fig no.7.1.5: Structure of Quercetin

Fig no.7.1.6: Quercetin

Antioxidant capacity:

Free radical scavenging: By donating electrons to neutralize free radicals, quercetin's five hydroxyl groups—especially those in the B and C rings—help avoid cellular damage.

Taking direct action against ROS, RNS, and RCS Reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive chlorine species (RCS) can all be directly captured by it.

Chelation of metal ions: By chelating transition-metal ions, quercetin can function as a reducing agent by preventing them from starting chain reactions mediated by free radicals.

Modulation of cellular pathways: It can control the expression of genes linked to oxidative stress and have an impact on cellular signaling pathways.

Increasing endogenous antioxidants: Quercetin can raise glutathione (GSH) levels, an antioxidant that is essential for the body's defense systems against oxidative damage.

METHODOLOGY IDENTIFIED:

Pre formulation parameter

Organoleptic characteristic:

The herbal medication's color, taste, odor, and appearance will be determined

Solubility:

 A variety of solvents, including water, methanol, and ethanol, are used to evaluate the solubility of herbal extract.

Melting point:

Determining the herbal extract's melting point is crucial for indicating the safe storage limit. The melting point of herbal extract is ascertained using the capillary method, which involves gathering and storing capillaries in a capillary device. It is observed that the product dissolves gradually, and occasionally the melting point shuts after the product has fully melted.

Spectroscopy in the infrared (IR):

The potassium bromide particle method was employed to record the infrared spectra of herbal extracts in the 400–4000 cm-1 range. A Shimadzu FT will be used to compare the interaction of the FT-IR methods with the now-IR spectrophotometer, model IR affinity 1CE8,9.

Herbal extract calibration curve:

Herbal extracts will be used to create a calibration curve. The dissolving medium will be phosphate buffered at pH 6.8. Ten milligrams of extract should be weighed out and diluted in one hundred milliliters of phosphate buffer.The solutions will be separated into the following categories: 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ug/ml. Plot the absorbance against the concentration after measuring the difference's absorbance using ultraviolet (UV) spectroscopy.

Post Formulation Studies:

Particle Size:

Using an optical microscope equipped with a calibrated ocular micrometer, measure the diameter of randomly chosen beads and note the average size.

Particle Size:

Using an optical microscope equipped with a calibrated ocular micrometer, measure the diameter of randomly chosen beads and note the average size.

Swelling Time:

Put dry beads in buffer and note how long it takes for the bead weight to stay constant, a sign of equilibrium swelling.

Consistency:

For the duration of the study, keep the beads at 4°C and frequently check for changes in size, color, shape, or structural integrity.

Shape:

Examine beads using a stereomicroscope to record any anomalies and assess sphericity and uniformity.

METHOD:

Procedure:

Weigh APIs (Green tea, Boswellia serrata, Quercetin)

?

Dissolve APIs in distilled water

?

Add sorbitol (stabilizer) and poloxamer (surfactant)

?

Add sodium alginate and pectin → Stir to form uniform polymeric solution

?

Prepare chitosan solution separately in mild acid

?

Add chitosan solution to drug–polymer mixture

?

Load final mixture into syringe

?

Extrude dropwise into CaCl? solution (cross-linking bath)

?

Formation of hydrogel beads by ionic gelation

?

Allow curing for required time

?

Collect beads and wash with distilled water

?

Dry beads at controlled temperature until constant weight

Formulation table:

Table no.1.7 :Formulation table